Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier

Y Gilgun-Sherki, E Melamed, D Offen - Neuropharmacology, 2001 - Elsevier
Oxidative stress (OS) has been implicated in the pathophysiology of many neurological,
particularly neurodegenerative diseases. OS can cause cellular damage and subsequent cell …

[PDF][PDF] VPS35 mutations in Parkinson disease

…, A Krygowska-Wajs, T Lynch, E Melamed… - The American Journal of …, 2011 - cell.com
The identification of genetic causes for Mendelian disorders has been based on the collection
of multi-incident families, linkage analysis, and sequencing of genes in candidate intervals…

[HTML][HTML] A double-blind, delayed-start trial of rasagiline in Parkinson's disease

…, A Lang, W Langston, E Melamed… - … England Journal of …, 2009 - Mass Medical Soc
Background A therapy that slows disease progression is the major unmet need in Parkinson's
disease. Methods In this double-blind trial, we examined the possibility that rasagiline has …

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy

Y Gilgun-Sherki, E Melamed, D Offen - Journal of neurology, 2004 - Springer
Accumulating data indicate that oxidative stress (OS) plays a major role in the pathogenesis
of multiple sclerosis (MS). Reactive oxygen species (ROS), leading to OS, generated in …

Antioxidant therapy in acute central nervous system injury: current state

Y Gilgun-Sherki, Z Rosenbaum, E Melamed… - Pharmacological …, 2002 - ASPET
Free radicals are highly reactive molecules generated predominantly during cellular respiration
and normal metabolism. Imbalance between cellular production of free radicals and the …

Validation of the freezing of gait questionnaire in patients with Parkinson's disease

…, O Rascol, DJ Brooks, E Melamed… - … : official journal of the …, 2009 - Wiley Online Library
To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease
(PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 …

[HTML][HTML] The natural history of multiple system atrophy: a prospective European cohort study

…, C Sampaio, M Coelho, R Djaldetti, E Melamed… - The lancet …, 2013 - thelancet.com
Background Multiple system atrophy (MSA) is a fatal and still poorly understood degenerative
movement disorder that is characterised by autonomic failure, cerebellar ataxia, and …

Levodopa in the treatment of Parkinson's disease: current controversies

…, WJ Langston, P LeWitt, E Melamed… - Movement …, 2004 - Wiley Online Library
Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD)
and the “gold standard” against which new agents must be compared. However, there …

Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization

F Hefti, E Melamed, RJ Wurtman - Brain research, 1980 - Elsevier
Various doses of 6-hydroxydopamine injected into the rat substantia nigra produced partial,
dose-dependent lesions of the dopaminergic nigrostriatal tract. The resulting reduction in …

The “dying-back” phenomenon of motor neurons in ALS

M Dadon-Nachum, E Melamed, D Offen - Journal of Molecular …, 2011 - Springer
Amyotrophic lateral sclerosis (ALS) is a lethal disease, characterized by progressive death
of motor neurons with unknown etiology. Evidence from animal models indicates that …